MeganMO'MearaMD

PubMed

• 47 citations
  A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML
  Amir T. Fathi, Harry P. Erba, Jeffrey E. Lancet, Eytan M. Stein, Farhad Ravandi, Stefan Faderl, Roland B. Walter, Anjali S. Advani, Daniel J. DeAngelo, Tibor Kovacsovi...> ;Blood. 2018 Sep 13
• 25 citations
  Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells In Vivo.
  Denise L. Cecil, Meredith Slota, Megan M. O'Meara, Benjamin Curtis, Ekram Gad, Yushe Dang, Dan Herendeen, Lauren Rastetter, Mary L. Disis> ;Clinical Cancer Research. 2017 Jul 1
• 38 citations
  Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy
  Ajay K. Gopal, Nancy L. Bartlett, Andres Forero-Torres, Anas Younes, Robert T. Chen, Jonathan W. Friedberg, Jeffrey Matous, Andrei R. Shustov, Scott E. Smith, Jasmine ...> ;Leukemia & Lymphoma. 2014 Feb 24
• 56 citations
  A Multiantigen Vaccine Targeting Neu, IGFBP-2, and IGF-IR Prevents Tumor Progression in Mice with Preinvasive Breast Disease
  Mary L. Disis, Ekram Gad, Dan Herendeen, Vy P. Lai, Kyong Hwa Park, Denise L. Cecil, Megan M. O'Meara, Piper M. Treuting, Ronald A. Lubet> ;Cancer Prevention Research. 2013 Dec 1
• 12 citations
  Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept.
  Megan Marie O'Meara, Mary L. Disis> ;Omics. 2011 Sep 1
• Limiting the daily total nucleated cell dose of cryopreserved peripheral blood stem cell products for autologous transplantation improves infusion-related safety with ...
  Khera, N., Jinneman, J., Storer, B.E., Heimfeld, S., O'Meara, M.M., Chauncey, T.R., Lee, S.J., Linenberger, M.> ;Biol Blood Marrow Transplant. 2012 Feb
• Persistent immunity and survival after immunization with a HER2/neu (HER2) vaccine.
  Salazar LG, Goodell V, O'Meara M, Knutson K, Dang Y, Dela Rosa C, Guthrie KA, Disis ML> ;J. Clin. Oncol.. 2009-05-20
• 53 citations
  Aberrant methylation of the maspin promoter is an early event in human breast cancer.
  Bernard W. Futscher, Megan M. O'Meara, Christina J. Kim, Margaret A. Rennels, Di Lu, Lynn M. Gruman, Richard E.B. Seftor, Mary J.C. Hendrix, Frederick E. Domann> ;Neoplasia. 2004 Jul 1
• Join now to see all

Lectures

• A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a No... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018